What is Provexis plc?
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide.
PXS · Verdict
Moderate reward · moderate risk
PXS stands out on balance sheet and volatility, but watch the cash flow signal.
Based on 88% data coverage
PXS · Verdict
Current ratio 4.08
Top decile vs peers
Rev +49.1% CAGR · earnings +5.5%
-26% free-cash-flow margin
-35% net margin · -125% ROE
Model-based scoring. For information only — not financial advice.
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 31.08M.
The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.